Skip to main content
Top
Gepubliceerd in: Quality of Life Research 6/2018

19-02-2018

Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study

Auteurs: Maria Stepanova, Fatema Nader, Christophe Bureau, Danielle Adebayo, Laure Elkrief, Dominique Valla, Markus Peck-Radosavljevic, Anne McCune, Victor Vargas, Macarena Simon-Talero, Juan Cordoba, Paolo Angeli, Silvia Rossi, Stewart MacDonald, Jeroen Capel, Rajiv Jalan, Zobair M. Younossi

Gepubliceerd in: Quality of Life Research | Uitgave 6/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Background

Refractory ascites (RA) is a complication of cirrhosis which is treated with large volume paracentesis (LVP) as the standard of care. Alfapump® system is a fully implantable pump system which reduces the need for LVP. The aim was to assess health-related quality of life (HRQL) in patients treated with alfapump® versus LVP.

Methods

The data were collected in a multicenter open-label randomized controlled trial (clinicaltrials.gov #NCT01528410). Subjects with cirrhosis Child–Pugh class B or C accompanied by RA were randomized to receive alfapump® or LVP. The SF-36v2 and CLDQ scores were compared between the two treatment arms at screening and monthly during treatment.

Results

Of 60 subjects randomized, HRQL data were available for 58 (N = 27 received alfapump® and N = 31 received LVP only). At baseline, no differences were seen between the treatment arms (all p > 0.05): age 61.9 ± 8.4, 79.3% male, MELD scores 11.7 ± 3.3, 85.2% Child–Pugh class B, 70.7% had alcoholic cirrhosis. The mean number of LVP events/subject was lower in alfapump® than LVP (1.1 vs. 8.6, p < 0.001). The HRQL scores showed a moderate improvement from the baseline levels in subjects treated with alfapump® (p < 0.05 for abdominal and activity scores of CLDQ) but not with LVP (all one-sided p > 0.05) in the first 3 months. Multivariate analysis showed that treatment with alfapump® was independently associated with better HRQL at 3 months (total CLDQ score: beta = 0.67 ± 0.33, p = 0.05).

Conclusion

As compared to LVP, the use of alfapump® system is associated with both a reduction in the number of LVP events and improvement of health-related quality of life.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Moore, C. M., & Van Thiel, D. H. (2013). Cirrhotic ascites review: Pathophysiology, diagnosis and management. World Journal of Hepatology, 5(5), 251–263.CrossRefPubMedPubMedCentral Moore, C. M., & Van Thiel, D. H. (2013). Cirrhotic ascites review: Pathophysiology, diagnosis and management. World Journal of Hepatology, 5(5), 251–263.CrossRefPubMedPubMedCentral
2.
go back to reference Planas, R., Montoliu, S., Ballesté, B., Rivera, M., Miquel, M., Masnou, H., et al. (2006). Natural history of patients hospitalized for management of cirrhotic ascites. Clinical Gastroenterology and Hepatology, 4(11), 1385–1394.CrossRefPubMed Planas, R., Montoliu, S., Ballesté, B., Rivera, M., Miquel, M., Masnou, H., et al. (2006). Natural history of patients hospitalized for management of cirrhotic ascites. Clinical Gastroenterology and Hepatology, 4(11), 1385–1394.CrossRefPubMed
3.
go back to reference Runyon, B. A., & AASLD Practice Guidelines Committee. (2009). Management of adult patients with ascites due to cirrhosis: An update. Hepatology, 49(6), 2087–2107.CrossRefPubMed Runyon, B. A., & AASLD Practice Guidelines Committee. (2009). Management of adult patients with ascites due to cirrhosis: An update. Hepatology, 49(6), 2087–2107.CrossRefPubMed
4.
go back to reference European Association for the Study of the Liver. (2010). EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journal of Hepatology, 53(3):397–417.CrossRef European Association for the Study of the Liver. (2010). EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journal of Hepatology, 53(3):397–417.CrossRef
5.
go back to reference Barsuk, J. H., Cohen, E. R., Feinglass, J., McGaghie, W. C., & Wayne, D. B. (2013). Clinical outcomes after bedside and interventional radiology paracentesis procedures. American Journal of Medicine, 126(4), 349–3 56.CrossRefPubMed Barsuk, J. H., Cohen, E. R., Feinglass, J., McGaghie, W. C., & Wayne, D. B. (2013). Clinical outcomes after bedside and interventional radiology paracentesis procedures. American Journal of Medicine, 126(4), 349–3 56.CrossRefPubMed
6.
7.
go back to reference Smith, M., & Durham, J. (2016). Evolving indications for TIPS. Techniques in Vascular and Interventional Radiology, 19(1), 36–41.CrossRefPubMed Smith, M., & Durham, J. (2016). Evolving indications for TIPS. Techniques in Vascular and Interventional Radiology, 19(1), 36–41.CrossRefPubMed
8.
go back to reference Copelan, A., Kapoor, B., & Sands, M. (2014). Transjugular intrahepatic portosystemic shunt: Indications, contraindications, and patient work-up. Seminars Interventional Radiology, 31(3), 235–242.CrossRef Copelan, A., Kapoor, B., & Sands, M. (2014). Transjugular intrahepatic portosystemic shunt: Indications, contraindications, and patient work-up. Seminars Interventional Radiology, 31(3), 235–242.CrossRef
9.
go back to reference American College of Radiology, Society for Pediatric Radiology, and Society for Interventional Radiology. (2014). ACR-SIR-SPR practice parameter for the creation of a transjugular intrahepatic portosystemic shunt (TIPS), Amended 2014 (Resolution 39). Practice parameters and technical standards, pp. 1–22. American College of Radiology, Society for Pediatric Radiology, and Society for Interventional Radiology. (2014). ACR-SIR-SPR practice parameter for the creation of a transjugular intrahepatic portosystemic shunt (TIPS), Amended 2014 (Resolution 39). Practice parameters and technical standards, pp. 1–22.
10.
go back to reference Teiusanu, A., Andrei, M., Arbanas, T., Nicolaie, T., & Diculescu, M. (2012). Nutritional status in cirrhotic patients. Maedica (Buchar), 7(4), 284–289. Teiusanu, A., Andrei, M., Arbanas, T., Nicolaie, T., & Diculescu, M. (2012). Nutritional status in cirrhotic patients. Maedica (Buchar), 7(4), 284–289.
11.
go back to reference Sorrentino, P., Castaldo, G., Tarantino, L., Bracigliano, A., Perrella, A., Perrella, O., et al. (2012). Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing repeated paracentesis. Journal of Gastroenterology and Hepatology, 27(4), 813–822.CrossRefPubMed Sorrentino, P., Castaldo, G., Tarantino, L., Bracigliano, A., Perrella, A., Perrella, O., et al. (2012). Preservation of nutritional-status in patients with refractory ascites due to hepatic cirrhosis who are undergoing repeated paracentesis. Journal of Gastroenterology and Hepatology, 27(4), 813–822.CrossRefPubMed
12.
go back to reference Younossi, Z. M., Boparai, N., McCormick, M., Price, L. L., & Guyatt, G. (2001). Assessment of utilities and health-related quality of life in patients with chronic liver disease. American Journal of Gastroenterology, 96(2), 579–583.CrossRefPubMed Younossi, Z. M., Boparai, N., McCormick, M., Price, L. L., & Guyatt, G. (2001). Assessment of utilities and health-related quality of life in patients with chronic liver disease. American Journal of Gastroenterology, 96(2), 579–583.CrossRefPubMed
13.
go back to reference Solà, E., Watson, H., Graupera, I., Turón, F., Barreto, R., Rodríguez, E., et al. (2012). Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema. Journal of Hepatology, 57(6), 1199 – 206.CrossRefPubMed Solà, E., Watson, H., Graupera, I., Turón, F., Barreto, R., Rodríguez, E., et al. (2012). Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema. Journal of Hepatology, 57(6), 1199 – 206.CrossRefPubMed
14.
go back to reference Orr, J. G., Homer, T., Ternent, L., Newton, J., McNeil, C. J., Hudson, M., et al. (2014). Health related quality of life in people with advanced chronic liver disease. Journal of Hepatology, 61(5), 1158–1165.CrossRefPubMed Orr, J. G., Homer, T., Ternent, L., Newton, J., McNeil, C. J., Hudson, M., et al. (2014). Health related quality of life in people with advanced chronic liver disease. Journal of Hepatology, 61(5), 1158–1165.CrossRefPubMed
15.
go back to reference Bhanji, R. A., Carey, E. J., & Watt, K. D. (2017). Review article: Maximising quality of life while aspiring for quantity of life in end-stage liver disease. Alimentary Pharmacology and Therapy, 46(1), 16–25.CrossRef Bhanji, R. A., Carey, E. J., & Watt, K. D. (2017). Review article: Maximising quality of life while aspiring for quantity of life in end-stage liver disease. Alimentary Pharmacology and Therapy, 46(1), 16–25.CrossRef
16.
go back to reference Jara, M., Bednarsch, J., Malinowski, M., Lüttgert, K., Orr, J., Puhl, G., Seehofer, D., Neuhaus, P., & Stockmann, M. (2014). Predictors of quality of life in patients evaluated for liver transplantation. Clinical Transplantation, 28(12), 1331–1338.CrossRefPubMed Jara, M., Bednarsch, J., Malinowski, M., Lüttgert, K., Orr, J., Puhl, G., Seehofer, D., Neuhaus, P., & Stockmann, M. (2014). Predictors of quality of life in patients evaluated for liver transplantation. Clinical Transplantation, 28(12), 1331–1338.CrossRefPubMed
18.
go back to reference Moore, K. P., & Aithal, G. P. (2006). Guidelines on the management of ascites in cirrhosis. Gut, 55(Suppl 6), vi1–12. Moore, K. P., & Aithal, G. P. (2006). Guidelines on the management of ascites in cirrhosis. Gut, 55(Suppl 6), vi1–12.
19.
go back to reference Ware, J. E. Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed Ware, J. E. Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed
20.
go back to reference Kharroubi, S. A., Brazier, J. E., Roberts, J., O’Hagan, A. (2007). Modelling SF-6D health state preference data using a nonparametric Bayesian method. Journal of Health Economics, 26(3), 597–612.CrossRefPubMed Kharroubi, S. A., Brazier, J. E., Roberts, J., O’Hagan, A. (2007). Modelling SF-6D health state preference data using a nonparametric Bayesian method. Journal of Health Economics, 26(3), 597–612.CrossRefPubMed
21.
go back to reference Younossi, Z. M., Stepanova, M., & Henry, L. (2016). Performance and validation of Chronic Liver Disease Questionnaire-hepatitis C version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C. Value Health, 19(5), 544–551.CrossRefPubMed Younossi, Z. M., Stepanova, M., & Henry, L. (2016). Performance and validation of Chronic Liver Disease Questionnaire-hepatitis C version (CLDQ-HCV) in clinical trials of patients with chronic hepatitis C. Value Health, 19(5), 544–551.CrossRefPubMed
22.
go back to reference Ware, J. E., Kosinski, M., Bjorner, J. B., Turner-Bowker, D. M., Gandek, B., & Maruish, M. E. (2007). User’s manual for the SF-36v2 health survey (2nd ed.). Lincoln, RI: Quality Metric Incorporated. Ware, J. E., Kosinski, M., Bjorner, J. B., Turner-Bowker, D. M., Gandek, B., & Maruish, M. E. (2007). User’s manual for the SF-36v2 health survey (2nd ed.). Lincoln, RI: Quality Metric Incorporated.
23.
go back to reference Fryback, D. G., Dunham, N. C., Palta, M., Hanmer, J., Buechner, J., Cherepanov, D., et al. (2007). US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Medical Care, 45(12), 1162–1170.CrossRefPubMedPubMedCentral Fryback, D. G., Dunham, N. C., Palta, M., Hanmer, J., Buechner, J., Cherepanov, D., et al. (2007). US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Medical Care, 45(12), 1162–1170.CrossRefPubMedPubMedCentral
24.
go back to reference Younossi, Z. M., Guyatt, G., Kiwi, M., Boparai, N., & King, D. (1999). Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut, 45(2), 295–300.CrossRefPubMedPubMedCentral Younossi, Z. M., Guyatt, G., Kiwi, M., Boparai, N., & King, D. (1999). Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut, 45(2), 295–300.CrossRefPubMedPubMedCentral
25.
go back to reference Sayiner, M., Stepanova, M., Pham, H., Noor, B., Walters, M., & Younossi, Z. M. (2016). Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterology, 3(1), e000106.CrossRefPubMedPubMedCentral Sayiner, M., Stepanova, M., Pham, H., Noor, B., Walters, M., & Younossi, Z. M. (2016). Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease. BMJ Open Gastroenterology, 3(1), e000106.CrossRefPubMedPubMedCentral
26.
go back to reference Campbell, M. S., Brensinger, C. M., Sanyal, A. J., Gennings, C., Wong, F., Kowdley, K. V., et al. (2005). Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology, 42(3), 635–640.CrossRefPubMed Campbell, M. S., Brensinger, C. M., Sanyal, A. J., Gennings, C., Wong, F., Kowdley, K. V., et al. (2005). Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology, 42(3), 635–640.CrossRefPubMed
27.
go back to reference Afendy, A., Kallman, J. B., Stepanova, M., Younoszai, Z., Aquino, R. D., Bianchi, G., Marchesini, G., & Younossi, Z. M. (2009). Predictors of health-related quality of life in patients with chronic liver disease. Alimentary Pharmacology Therapy, 30(5), 469–476.CrossRef Afendy, A., Kallman, J. B., Stepanova, M., Younoszai, Z., Aquino, R. D., Bianchi, G., Marchesini, G., & Younossi, Z. M. (2009). Predictors of health-related quality of life in patients with chronic liver disease. Alimentary Pharmacology Therapy, 30(5), 469–476.CrossRef
28.
go back to reference Adebayo, D., Bureau, C., Valla, D., Peck-Radosavljevic, M., McCune, A., Vargas, V., et al. (2015). Alfapump® system versus large volume paracentesis in the treatment of refractory ascites. A multicenter randomised controlled study. Journalof Hepatology, 62(Suppl 2), S849–S850.CrossRef Adebayo, D., Bureau, C., Valla, D., Peck-Radosavljevic, M., McCune, A., Vargas, V., et al. (2015). Alfapump® system versus large volume paracentesis in the treatment of refractory ascites. A multicenter randomised controlled study. Journalof Hepatology, 62(Suppl 2), S849–S850.CrossRef
29.
go back to reference Paparrigopoulos, T., Tzavellas, E., Karaiskos, D., Liappas, I. (2007). Should impaired liver function be held responsible for cognitive impairment and poor health-related quality of life in alcoholic cirrhosis? Hepatology, 46(3):950; author reply 951.CrossRefPubMed Paparrigopoulos, T., Tzavellas, E., Karaiskos, D., Liappas, I. (2007). Should impaired liver function be held responsible for cognitive impairment and poor health-related quality of life in alcoholic cirrhosis? Hepatology, 46(3):950; author reply 951.CrossRefPubMed
31.
go back to reference Spiegel, B. M., Younossi, Z. M., Hays, R. D., Revicki, D., Robbins, S., & Kanwal, F. (2005). Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology, 41(4), 790–800.CrossRefPubMed Spiegel, B. M., Younossi, Z. M., Hays, R. D., Revicki, D., Robbins, S., & Kanwal, F. (2005). Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment. Hepatology, 41(4), 790–800.CrossRefPubMed
32.
go back to reference Walters, S. J., & Brazier, J. E. (2003). What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health and Quality Life Outcomes, 1(1), 4.CrossRef Walters, S. J., & Brazier, J. E. (2003). What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health and Quality Life Outcomes, 1(1), 4.CrossRef
Metagegevens
Titel
Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study
Auteurs
Maria Stepanova
Fatema Nader
Christophe Bureau
Danielle Adebayo
Laure Elkrief
Dominique Valla
Markus Peck-Radosavljevic
Anne McCune
Victor Vargas
Macarena Simon-Talero
Juan Cordoba
Paolo Angeli
Silvia Rossi
Stewart MacDonald
Jeroen Capel
Rajiv Jalan
Zobair M. Younossi
Publicatiedatum
19-02-2018
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 6/2018
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-1813-8

Andere artikelen Uitgave 6/2018

Quality of Life Research 6/2018 Naar de uitgave